Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.
Sep 27, 2022 · Members in the News
CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it has entered into a preliminary agreement with EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry.
To read the press release, please click here.
Read NextProsoma Digital Therapeutics and EVERSANA Announce Commercialisation Partnership for New Therapeutic Supporting Mental Health and Behavioural Needs of Cancer Patients Sep 27 CHICAGO and WARSAW – September 26, 2022 – Prosoma Digital Therapeutics, innovators in reinventing healthcare for... read more